Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.

Haldar, Debashis, Janmohamed, Ashnila, Plant, Tim, Davidson, Matthew, Norman, Hannah, Russell, Emily, Serevina, Olivia, Chung, Kenneth, Qamar, Kashif, Gunson, Bridget K, Hansen, Bettina, Richter, Alex, Trivedi, Palak J and Hirschfield, Gideon M (2020) Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis. Liver international : official journal of the International Association for the Study of the Liver. ISSN 1478-3231. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

Full text not available from this repository.
Official URL: https://onlinelibrary.wiley.com/doi/10.1111/liv.14...

Abstract

BACKGROUND AND AIMS

A variety of auto-antibody assays are available as part of the clinical care of patients with liver disease. We sought to better understand the clinical utility of immune-serological testing in patients with primary biliary cholangitis (PBC).

METHODS

We retrospectively analyzed data from 2846 patients investigated for liver disease at a UK liver transplant center between 2001 and 2017. 499 patients with PBC were identified. Immune serology results were examined for their diagnostic utility and prognostic significance to predict transplant-free survival.

RESULTS

Anti-mitochondrial antibodies (AMA) were specific (94.5%) and sensitive (85.6%) for PBC; anti-nuclear antibodies (ANA) against glycoprotein-210 (gp210) and sp100 were specific (>98%) but not sensitive (<25%). The disease-specific ANAs were detectable in 29.6% of AMA-negative patients. Anti-gp210 auto-antibodies were significantly associated with elevated hepatic aminotransferases, bilirubin, and liver stiffness at presentation (P<0.010). Anti-gp210 auto-antibodies predicted non-response to ursodeoxycholic acid (UDCA) by GLOBE criteria (39.3% vs. 16.7%, P=0.005). Moreover, anti-gp210 was independently associated with death or liver transplantation (HR 3.22, 95% CI 1.49-6.96; P=0.003), after accounting for other significant baseline determinants of outcome. Moreover, the expression of anti-gp210 antibodies conferred an independent risk of death or transplantation (HR 4.13, 95% CI 1.85-9.22; P=0.001) after accounting for treatment response.

CONCLUSION

In our single centre cohort of patients with PBC the presence of anti-gp210 was associated with an adverse presenting phenotype, predicted treatment non-response and independently predicted reduced transplant-free survival.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: QW Microbiology. Immunology
WI Digestive system. Gastroenterology
Divisions: Planned IP Care > Gastroentrology
Related URLs:
Depositing User: Mrs Yolande Brookes
Date Deposited: 19 Nov 2020 16:20
Last Modified: 19 Nov 2020 16:20
URI: http://www.repository.uhblibrary.co.uk/id/eprint/3682

Actions (login required)

View Item View Item